ReviewFrontiers in immunology2017
Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- Glucocorticoid-induced TNF receptor ligand-dependent B-cell expansion of regulatory T cells as an immune cell therapy strategy.Blood immunology & cellular therapy · 2026Article
- Immune tolerance platforms to mitigate unwanted immune responses.Journal of pharmaceutical sciences · 2026Review
- Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.Journal of translational medicine · 2025Article
- Use of regulatory cells for achieving functional tolerance of pig heart xenotransplants in humans: a literature review.Frontiers in immunology · 2025Review
- Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy.Frontiers in immunology · 2024Review
- Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection.JCI insight · 2023Article
- The Molecular Role of Immune Cells in Dilated Cardiomyopathy.Medicina (Kaunas, Lithuania) · 2023Review
- Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies.GEN biotechnology · 2023Review
- Biomaterials-based nanoparticles conjugated to regulatory T cells provide a modular system for localized delivery of pharmacotherapeutic agents.Journal of biomedical materials research. Part A · 2023Article
- Study Design: Human Leukocyte Antigen Class I Molecule AKidney international reports · 2022Article
- Regulatory T Cells, a Viable Target Against Airway Allergic Inflammatory Responses in Asthma.Frontiers in immunology · 2022Review
- The emerging role of regulatory cell-based therapy in autoimmune disease.Frontiers in immunology · 2022Review
- Patients' Willingness and Perspectives Toward Chimeric Antigen Receptor T-Regulatory Cell Therapy for Inflammatory Bowel Diseases.Crohn's & colitis 360 · 2020Article
- Article
- Prospects of the Use of Cell Therapy to Induce Immune Tolerance.Frontiers in immunology · 2020Review
- Methods to manufacture regulatory T cells for cell therapy.Clinical and experimental immunology · 2019Review
- Emerging Cellular Therapies: T Cells and Beyond.Cells · 2019Article
- Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.JCI insight · 2019Article
- Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.JCI insight · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) are potent suppressors of immune responses and are currently being clinically tested for their potential to stop or control undesired immune responses in autoimmunity, hematopoietic stem cell transplantation, and solid organ transplantation. Current clinical approaches aim to boost Tregs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.